文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

新斯的明辅助治疗对感染性休克促炎细胞因子的影响:一项随机对照试验

Effect of Neostigmine on Attenuation of Proinflammatory Cytokines When Given as an Adjuvant Therapy in Septic Shock: A Randomized Control Trial.
PubMed 文献 · Crit Care Med · 2026-02-12
一句话结论在感染性休克患者中,新斯的明以0.2 mg/hr持续输注5天可降低第5天肿瘤坏死因子-α水平,并降低28天死亡率(26% vs 54%)。

该研究为单中心、前瞻性、随机、双盲、安慰剂对照试验,纳入成人ICU感染性休克患者,随机接受新斯的明0.2 mg/hr(2 mL/hr)或安慰剂持续输注5天。主要终点为肿瘤坏死因子-α水平下降,新斯的明组第5天为40 ± 36 pg/mL,显著低于对照组的67 ± 43 pg/mL(p = 0.002)。次要终点中,新斯的明组序贯器官衰竭评估评分从第1天到第5天显著降低(p < 0.001),28天死亡率也低于对照组(26% vs 54%,p = 0.02)。作者认为新斯的明输注通过增强乙酰胆碱释放调节胆碱能抗炎通路,从而减轻感染性休克患者的全身炎症和细胞因子水平。

要点

  • 感染性休克成人ICU患者随机接受新斯的明0.2 mg/hr(2 mL/hr)或安慰剂持续输注5天,第5天肿瘤坏死因子-α为新斯的明组40 ± 36 pg/mL vs 对照组67 ± 43 pg/mL(p = 0.002)。
  • 新斯的明组28天死亡率为26%,低于对照组的54%(p = 0.02)。
  • 新斯的明组序贯器官衰竭评估评分从第1天到第5天显著降低(p < 0.001)。
  • 该研究为单中心、前瞻性、随机、双盲、安慰剂对照试验,在成人ICU感染性休克患者中评估新斯的明辅助治疗。
  • 作者认为新斯的明输注通过增强乙酰胆碱释放调节胆碱能抗炎通路,降低感染性休克患者的全身炎症和细胞因子水平。

适用人群与场景

  • 成人ICU的感染性休克患者,来自一家三级学术医疗机构的单一成人ICU。

处置流程与药物剂量

  • 新斯的明组以固定速率0.2 mg/hr(2 mL/hr)持续输注,研究药物给药5天;对照组给予安慰剂。

研究设计与关键结果

  • 研究类型为单中心、前瞻性、随机、双盲、安慰剂对照试验;人群为成人ICU感染性休克患者;干预为新斯的明0.2 mg/hr(2 mL/hr)持续输注5天 vs 安慰剂。
  • 主要终点:第5天肿瘤坏死因子-α水平为新斯的明组40 ± 36 pg/mL vs 对照组67 ± 43 pg/mL(p = 0.002)。
  • 关键次要终点:新斯的明组序贯器官衰竭评估评分从第1天到第5天显著降低(p < 0.001);28天死亡率为新斯的明组26% vs 对照组54%(p = 0.02)。
  • 其他次要终点包括血流动力学参数、感染性休克逆转和降钙素原水平变化,原文未报告具体结果数值。

证据类型、等级与局限

  • 证据类型:单中心、前瞻性、随机、双盲、安慰剂对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为新斯的明输注通过增强乙酰胆碱释放调节胆碱能抗炎通路,降低感染性休克患者的全身炎症和细胞因子水平。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: The cholinergic anti-inflammatory pathway (ChAP) is the key regulator of the dysregulated cytokine storm in sepsis, with acetylcholine acting on alpha-7 nicotinic acetylcholine receptors (α7nAChRs) to suppress excessive inflammation. The objective of this study was to evaluate whether neostigmine administration modulates the inflammatory response in sepsis by enhancing cholinergic anti-inflammatory activity.

DESIGN: A single-center, prospective, randomized, double-blinded, placebo-controlled study.

SETTING: One adult ICU at a tertiary academic medical institution.

INTERVENTION: Patients were randomized to receive neostigmine at a fixed rate of 0.2 mg/hr (2 mL/hr) or placebo. Study drug was administered for 5 days.

MEASUREMENTS AND RESULTS: The primary outcome measure was decrease in tumor necrosis factor-alpha levels, in patients treated with neostigmine adjuvant therapy vs. the standard therapy. The secondary outcomes were hemodynamic parameters, septic shock reversal, changes in procalcitonin levels, and organ failure scores. The mean tumor necrosis factor-alpha levels were significantly lower in the neostigmine group (40 ± 36 pg/mL, mean ± sd ) on day 5 as compared with the control group (67 ± 43 pg/mL; p = 0.002). There was a significant reduction in Sequential Organ Failure Assessment scores from day 1 to day 5 ( p < 0.001) and 28-day mortality was also lower in the neostigmine group (26%) as compared with control group (54%, p = 0.02).

CONCLUSIONS: The neostigmine infusion modulates the ChAP by potentiating the acetylcholine release leading to reduced systemic inflammation and decreased cytokine levels in septic shock patients. (Clinical Trial Registry of India number: CTRI/2023/07/ 055054).

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Bashni T M, Kothari N, Sharma A, et al. Effect of Neostigmine on Attenuation of Proinflammatory Cytokines When Given as an Adjuvant Therapy in Septic Shock: A Randomized Control Trial. Crit Care Med. 2026. PMID: 41677407. doi:10.1097/CCM.0000000000007051

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。